Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $10.10.
Several equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Piper Sandler lowered their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, January 21st.
View Our Latest Stock Report on CRDF
Cardiff Oncology Stock Performance
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 87.91% and a negative net margin of 8,527.43%.The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.09 million. On average, research analysts forecast that Cardiff Oncology will post -0.6 EPS for the current fiscal year.
Institutional Investors Weigh In On Cardiff Oncology
A number of institutional investors have recently modified their holdings of CRDF. Franklin Resources Inc. acquired a new stake in shares of Cardiff Oncology during the 4th quarter valued at $3,388,000. Laurion Capital Management LP boosted its stake in shares of Cardiff Oncology by 37.2% during the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock valued at $5,080,000 after buying an additional 668,590 shares during the period. Acorn Capital Advisors LLC boosted its stake in shares of Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after buying an additional 553,317 shares during the period. Millennium Management LLC boosted its stake in shares of Cardiff Oncology by 441.5% during the 4th quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock valued at $546,000 after buying an additional 158,519 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Cardiff Oncology by 7.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after buying an additional 104,409 shares during the period. Institutional investors and hedge funds own 16.29% of the company’s stock.
About Cardiff Oncology
Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.
Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.
Featured Stories
- Five stocks we like better than Cardiff Oncology
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
